Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Company Overview

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $2.71 to $2.98
• 50-Day Range: $2.02 to $3.60
• 52-Week Range: $1.78 to $11.40
• Volume: 638,090 shs
• Average Volume: 385,067 shs
• Market Capitalization: $122.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.50
• Consensus Rating: Buy

Kyverna Therapeutics Stock Analysis - MarketRank™

Kyverna Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 799th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Kyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kyverna Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyverna Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyverna Therapeutics is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kyverna Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.79% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kyverna Therapeutics does not currently pay a dividend.

Dividend Growth

Kyverna Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.79% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.47

News Sentiment

Kyverna Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Kyverna Therapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

2 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 18.08% of the stock of Kyverna Therapeutics is held by institutions.

KYTX Stock Analysis - Frequently Asked Questions

How have KYTX shares performed this year?

Kyverna Therapeutics' stock was trading at $3.74 at the start of the year. Since then, KYTX shares have decreased by 24.3% and is now trading at $2.83.
View the best growth stocks for 2025 here.

How were Kyverna Therapeutics' earnings last quarter?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($1.03) earnings per share for the quarter, beating analysts' consensus estimates of ($1.21) by $0.18.

When did Kyverna Therapeutics IPO?

Kyverna Therapeutics (KYTX) raised $319 million in an IPO on Thursday, February 8th 2024. The company issued 14,500,000 shares at $22.00 per share.

Who are Kyverna Therapeutics' major shareholders?

Top institutional shareholders of Kyverna Therapeutics include Kera Capital Partners Inc. (0.98%).
View institutional ownership trends.

How do I buy shares of Kyverna Therapeutics?

Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kyverna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/02/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KYTX
• Previous Symbol: NASDAQ:KYTX
• CIK: 1994702
• Web: kyvernatx.com
• Phone: 510-626-8331
• Fax: N/A
• Employees: 96
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $18.50
• High Stock Price Target: $33.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +543.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.66%
• Return on Assets: -45.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.44
• Quick Ratio: 7.44

Sales & Book Value

• Annual Sales: $7.03 million
• Price / Sales: 17.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.17 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 43,220,000
• Free Float: N/A
• Market Cap: $124.26 million
• Optionable: Optionable
• Beta: 2.94